need
novel
therapeut
option
fight
herpesviru
infect
still
persist
herein
report
design
synthesi
antivir
evalu
new
famili
nonnucleosid
antivir
deriv
x
alkyl
uracil
deriv
previous
report
inhibitor
human
cytomegaloviru
hcmv
introduct
n
acetamid
side
chain
n
increas
potenc
widen
activ
spectrum
activ
compound
seri
exhibit
submicromolar
activ
differ
viral
strain
hcmv
varicella
zoster
viru
vzv
replic
hel
cell
cultur
inact
dna
rna
virus
includ
herp
simplex
viru
point
novel
mechan
antivir
action
human
cytomegaloviru
hcmv
human
varicella
zoster
viru
vzv
also
known
human
belong
viral
famili
known
herpesvirida
despit
modern
prevent
treatment
strategi
remain
common
opportunist
pathogen
associ
seriou
morbid
mortal
particularli
immunocompromis
individu
transplant
recipi
aid
patient
drug
current
licens
treatment
hcmv
vzv
infect
fig
target
viral
dna
polymeras
unfortun
associ
sever
toxic
issu
includ
marrow
toxic
ganciclovir
valganciclovir
cidofovir
renal
toxic
foscarnet
cidofovir
emerg
drug
resist
also
signific
problem
moreov
understand
full
spectrum
risk
hcmv
infect
interact
host
immun
system
remain
far
complet
past
two
decad
seen
progress
toward
novel
treatment
herpesvirus
need
better
drug
exhibit
improv
toxic
profil
persist
previous
describ
seri
x
phenoxi
alkyl
uracil
deriv
found
exhibit
high
specif
promis
inhibitori
activ
hcmv
replic
hel
cell
cultur
ec
valu
within
lm
rang
result
provid
strong
impetu
explor
structureact
relationship
antivir
activ
spectrum
similar
scaffold
present
paper
describ
lead
develop
n
acetamid
deriv
fig
synthesi
compound
librari
reli
three
key
step
synthesi
x
phenoxi
alkyl
uracil
deriv
relat
compound
synthesi
acetamid
subsequ
conjug
realiz
target
compound
base
success
synthesi
sever
previous
report
compound
seri
analog
synthes
follow
classic
synthet
approach
report
scheme
first
set
deriv
character
focus
modif
aromat
ring
synthesi
compound
start
commerci
avail
phenol
r
treat
excess
xdibromoalkan
n
produc
bromid
accord
known
procedur
modifi
silyl
hilbertjohnson
reaction
condens
equimolar
amount
trimethylsilyloxi
pyrimidin
bromid
perform
absenc
solvent
afford
target
compound
yield
compound
compris
methylen
unit
respect
obtain
analog
manner
use
compound
scheme
intermedi
readili
obtain
via
acyl
commerci
avail
phenoxi
benzyloxi
anilin
chloroacetyl
chlorid
promot
anhydr
k
co
aprot
media
obtain
describ
previous
treatment
potassium
salt
uracil
deriv
anhydr
dmf
afford
target
compound
good
yield
scheme
avoid
possibl
complic
due
iodin
elimin
compound
obtain
employ
nah
base
target
compound
subsequ
isol
yield
order
obtain
benzophenon
deriv
appropri
build
block
obtain
somewhat
differ
order
first
acid
synthes
quantit
via
treatment
ethyl
bromoacet
presenc
k
co
follow
hydrolysi
use
lioh
accord
publish
procedur
subsequ
convers
acid
correspond
acyl
chlorid
follow
condens
ntrimethylsilyl
deriv
benzoyl
anilin
led
yield
scheme
note
util
basefre
condit
synthesi
avoid
byproduct
typic
aris
knoevenagel
condens
benzophenon
carbonyl
activ
methylen
acet
acid
residu
explor
sar
compound
design
second
set
analog
featur
modifi
spacer
link
n
uracil
aromat
moieti
synthesi
variou
target
structur
demand
differ
relat
approach
coppercatalyz
coupl
phenylmagnesium
bromid
excess
thf
media
produc
bromid
condens
trimethylsilyloxi
pyrimidin
afford
uracil
howev
unexpectedli
mediocr
yield
scheme
somewhat
surpris
sinc
previou
observ
reaction
involv
similar
x
phenoxi
alkyl
bromid
alkyl
agent
contrast
quit
effici
silyl
hilbertjohnson
reaction
trimethylsilyloxi
pyrimidin
alkyl
bromid
known
associ
releas
trimethylsilyl
bromid
subsequ
scheme
reagent
condit
chloroacetyl
chlorid
k
co
dce
h
b
k
co
dmf
rt
h
nah
dmf
rt
h
effici
cleav
dialkyl
ether
elev
temperatur
result
order
obtain
butyl
uracil
necessari
alkyl
uracil
tosyl
obtain
via
williamson
ether
synthesi
bromobenzyl
bromid
follow
condens
chlorid
presenc
pyridin
scheme
addit
analog
featur
two
oxygen
atom
spacer
chain
pursu
shown
scheme
chloromethyl
ether
obtain
via
classic
henri
method
condens
equimolar
amount
trimethylsilyloxi
pyrimidin
led
ethoxi
methyl
uracil
yield
reactiv
bromid
reaction
proce
rather
mild
condit
dce
ambient
temperatur
next
flexibl
spacer
replac
rigid
benzyl
moieti
introduc
n
uracil
employ
previous
report
procedur
outlin
scheme
trimethylsilyloxi
pyrimidin
benzyl
bromid
react
dce
reflux
h
give
final
investig
potenti
role
amid
nitrogen
methyl
methyl
iodidenah
dmf
success
produc
compound
yield
scheme
antivir
activ
target
compound
evalu
vitro
differ
human
herpesvirus
ie
hcmv
result
hcmv
vzv
summar
respect
tabl
result
reveal
major
target
compound
share
mark
inhibitori
properti
examin
result
hcmv
sar
studi
reveal
natur
r
substitu
significantli
influenc
antivir
activ
sinc
compound
show
select
ratio
cc
ec
hcmv
strain
lower
toxic
alter
cell
morpholog
compound
consid
basi
modif
notabl
natur
spacer
uracil
left
aromat
wing
significantli
influenc
antihcmv
activ
compound
exampl
elong
spacer
methylen
group
progress
lower
ec
valu
demonstr
n
n
n
n
n
specif
introduct
five
methylen
group
give
increas
activ
fold
howev
concomit
increas
cytotox
also
observ
replac
oxygen
atom
methylen
compound
result
loss
activ
point
potenti
role
ether
function
spacer
region
shift
posit
oxygen
aromat
moieti
markedli
affect
activ
chang
compar
introduct
addit
oxygen
compound
render
compound
complet
inact
use
rigid
spacer
compound
also
prove
unfavor
overal
incorpor
alkoxyphenyl
side
chain
prove
optim
interestingli
one
modif
made
uracil
moieti
prove
deleteri
substitut
h
uracil
iodin
render
complet
inact
next
sar
studi
involv
modif
right
wing
reveal
presenc
second
benzen
core
acetamid
side
chain
mandatori
inhibitori
properti
compound
investig
role
linker
aromat
residu
show
oxygen
provid
optim
activ
profil
correspond
methylen
analog
retain
similar
level
activ
cytotox
use
carbonyl
och
group
render
compound
significantli
less
activ
nmethyl
parent
signific
influenc
potenc
compound
show
similar
activ
trend
observ
antivzv
properti
target
compound
compound
block
vzv
replic
lm
oka
strain
compar
acyclovir
time
thymidin
kinas
defici
strain
also
suscept
sinc
thymidin
kinas
requir
activ
nucleosid
analog
eg
acyclovir
brivudin
like
compound
act
nonnucleosid
inhibitor
substitu
r
found
inact
note
hcmv
inhibit
elong
spacer
pronounc
posit
impact
antivzv
properti
compound
featur
methylen
unit
prove
activ
ec
p
lm
p
lm
oka
strain
respect
howev
increas
activ
accompani
higher
cytotox
spacer
modif
includ
oxygen
posit
shift
introduct
addit
oxygen
benzen
moieti
result
loss
activ
thu
natur
spacer
play
crucial
role
antivir
properti
term
substitu
introduct
substitu
uracil
render
compound
complet
inact
substitut
oxygen
linker
aromat
residu
acetamid
side
chain
right
wing
led
cytotox
methylen
deriv
less
potent
x
och
x
co
addit
nmethyl
deriv
compound
lack
phenoxi
core
indic
n
acetamid
side
chain
like
key
element
requir
antivir
properti
scaffold
interestingli
compound
inact
somewhat
surpris
sinc
antiherp
drug
target
viral
dna
polymeras
share
broad
spectrum
activ
variou
herpesvirus
mechan
action
compound
howev
remain
unclear
thu
investig
warrant
herein
describ
synthesi
preliminari
biolog
evalu
sar
studi
seri
novel
uracil
deriv
potenti
dual
hcmvvzv
agent
major
synthes
compound
exhibit
potent
antivir
activ
cell
cultur
experiment
data
undoubtedli
show
x
alkyl
substitu
n
n
acetamid
side
chain
n
uracil
key
element
respons
antihcmv
antivzv
activ
mode
action
report
seri
yet
fulli
elucid
publish
elsewher
studi
meantim
activ
compound
seri
repres
excel
start
point
optim
reagent
obtain
highest
grade
avail
sigma
acro
organ
use
without
purif
unless
otherwis
note
anhydr
dmf
isopropyl
alcohol
purchas
sigmaaldrich
co
anhydr
aceton
dce
etoac
obtain
distil
p
tlc
perform
merck
tlc
silica
gel
f
plate
elut
specifi
solvent
sampl
made
visual
uv
lamp
lc
franc
acro
organ
belgium
silica
gel
kieselgur
lm
use
column
chromatographi
yield
refer
spectroscop
h
c
nmr
homogen
materi
melt
point
determin
glass
capillari
meltemp
laboratori
devic
inc
usa
nmr
spectra
obtain
use
bruker
avanc
mhz
h
mhz
c
bruker
avanc
mhz
h
mhz
c
spectromet
dmsod
cdcl
tetramethylsilan
intern
standard
highresolut
mass
spectra
measur
bruker
microtof
ii
instrument
use
electrospray
ioniz
hresim
measur
run
posit
ion
mode
interfac
capillari
voltag
v
mass
rang
mz
mz
da
extern
intern
calibr
perform
esi
tune
mixtm
agil
technolog
syring
inject
use
solut
mecn
flow
rate
llmin
n
appli
dri
ga
interfac
temperatur
set
synthesi
character
data
report
previous
equimolar
mixtur
pentan
g
mmol
trimethylsilyloxi
pyrimidin
g
mmol
heat
h
result
melt
dissolv
etoac
ml
treat
iproh
ml
precipit
product
collect
purifi
shortcolumn
flash
chromatographi
use
etoacdc
subsequ
recrystal
mixtur
etoachexan
provid
desir
product
white
crystal
g
mp
equimolar
mixtur
g
mmol
trimethylsilyloxi
pyrimidin
g
mmol
heat
h
result
melt
dissolv
etoac
ml
treat
iproh
ml
precipit
filter
filtrat
evapor
taken
aceton
ml
etoac
ml
purifi
shortcolumn
flash
chromatographi
use
etoac
give
white
crystal
g
mp
r
f
ethyl
acet
mixtur
uracil
g
mmol
k
co
g
mmol
anhydr
dmf
ml
stir
min
cool
room
temperatur
butyl
ptoluenesulfon
g
mmol
ad
stir
continu
h
reaction
mixtur
filter
concentr
reduc
pressur
purifi
shortcolumn
flash
chromatographi
use
mixtur
chcl
etoh
analyt
sampl
recrystal
etoac
give
compound
solut
trimethylsilyloxi
pyrimidin
g
mmol
anhydr
methylen
chlorid
ml
ad
solut
ethoxi
methoxi
methyl
chlorid
g
mmol
methylen
chlorid
ml
stir
h
room
temperatur
ethanol
ml
ad
result
mixtur
stir
min
filter
evapor
dryness
reduc
pressur
purifi
shortcolumn
flash
chromatographi
use
mixtur
chcl
etoh
analyt
sampl
recrystal
ethyl
acet
give
compound
white
crystal
solut
trimethylsilyloxi
pyrimidin
g
mmol
bromophenoxi
benzylbromid
g
mmol
anhydr
dce
ml
heat
reflux
h
cool
room
temperatur
treat
iproh
ml
result
precipit
collect
purifi
shortcolumn
flash
chromatographi
use
mixtur
chcl
etoh
analyt
sampl
recrystal
mixtur
dmfiprohh
give
compound
white
crystal
g
mp
r
f
ethyl
acet
chloroacetyl
chlorid
ml
mmol
ad
dropwis
stir
mixtur
appropri
anilin
mmol
k
co
g
mmol
anhydr
dce
ml
reaction
mixtur
stir
h
allow
warm
room
temperatur
overnight
inorgan
materi
filter
pad
silica
gel
wash
dce
ml
filtrat
evapor
reduc
pressur
residu
purifi
recrystal
mixtur
hexaneethyl
acet
gener
procedur
synthesi
mixtur
appropri
uracil
mmol
k
co
g
mmol
anhydr
dmf
ml
stir
min
cool
room
temperatur
correspond
mmol
ad
stir
continu
h
reaction
mixtur
filter
concentr
reduc
pressur
purifi
shortcolumn
flash
chromatographi
use
dce
analyt
sampl
recrystal
mixtur
hexaneethyl
acet
confluent
cell
cultur
microtit
plate
inocul
ccid
viru
ccid
viru
dose
infect
cell
cultur
plaqu
form
unit
pfu
vzv
hcmv
presenc
vari
concentr
test
compound
viral
cytopath
plaqu
format
record
soon
reach
complet
control
virusinfect
cell
cultur
treat
test
compound
antivir
activ
express
ec
compound
concentr
requir
reduc
virusinduc
cytopathogen
viral
plaqu
format
inhibit
iii
b
rod
induc
cytopath
cem
cell
cultur
measur
microtit
plate
contain
cem
cellsml
infect
ccid
hiv
per
millilit
contain
appropri
dilut
test
compound
day
incub
co
control
humidifi
atmospher
cem
giant
syncytium
cell
format
examin
microscop
ec
effect
concentr
defin
compound
concentr
requir
inhibit
hivinduc
giant
cell
format
cytotox
measur
base
inhibit
cell
growth
hel
cell
seed
rate
cellswel
microtit
plate
allow
adher
prolifer
h
medium
contain
differ
concentr
test
compound
ad
day
incub
cell
number
determin
coulter
counter
cytostat
concentr
calcul
cc
compound
concentr
requir
reduc
cell
prolifer
rel
number
cell
untreat
control
cc
valu
estim
graphic
plot
number
cell
percentag
control
function
concentr
test
compound
altern
cytotox
test
compound
express
minimum
cytotox
concentr
mcc
compound
concentr
caus
microscop
detect
alter
cell
morpholog
select
index
calcul
ratio
cc
ec
